The pharmaceutical industry is bracing for an anticipated uptick in the prices of Azithromycin throughout the first quarter of xxxx. A combination of significant factors is likely to drive this increase, triggering a cascade of effects throughout the supply chain and affecting end-users across different markets.
Key Takeaways:
-
Rising respiratory illnesses and HMPV in Northern China boost Azithromycin demand.
-
The Chinese Lunar New Year will cause production slowdowns and API export delays.
-
Potential tariff hikes under the Trump administration are prompting importers to frontload shipments, raising freight volumes and Azithromycin prices.
-
Longer transit times around Africa are escalating shipping costs, adding pressure on Azithromycin prices.
-
Manufacturers and distributors are expected to implement proactive pricing and careful inventory management.
The rise in respiratory illnesses and Human Metapneumovirus (HMPV) cases in northern China is increasing demand for various respiratory-related medications, including antibiotics like Azithromycin, which is commonly used to treat secondary bacterial infections...
